National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant CyclophosphamideBronwen E. Shaw, Javier Bolaños‐Meade, Antonio Martin Jimenez-Jimenez et al.|Journal of Clinical Oncology|2021Cited by 217
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical TrialBronwen E. Shaw, Javier Bolaños‐Meade, Antonio Martin Jimenez-Jimenez et al.|Transplantation and Cellular Therapy|2022Cited by 55
Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703.Matthew J. Wieduwilt, Richard M. Stone, Jun Yin et al.|Journal of Clinical Oncology|2023Cited by 49
S117: CHEMOTHERAPY-FREE TREATMENT WITH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB FOR OLDER ADULTS WITH NEWLY-DIAGNOSED, PH-NEGATIVE, CD22-POSITIVE, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: ALLIANCE A041703Matthew J. Wieduwilt, Richard M. Stone, Jun Yin et al.|HemaSphere|2023Cited by 13
Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 ResultsMatthew J. Wieduwilt, Richard M. Stone, Jun Yin et al.|Journal of Clinical Oncology|2025Cited by 7